The First CAR-T Therapy Is Not Living Up to Expectations – Labiotech.eu (blog)
|
The First CAR–T Therapy Is Not Living Up to Expectations
Labiotech.eu (blog) Kymriah is currently waiting for FDA approval to extend the use of Kymriah to diffuse large B cell lymphoma in the US, as well as taking the therapy to Europe. But where Novartis is struggling to meet pricing and sales expectations, newcomers might … Gilead: Will Medicare Boost Yescarta Sales? |
